Monostep (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol supplies estrogenic activity while levonorgestrel provides progestogenic activity. Together they suppress the hypothalamic‑pituitary‑ovarian axis, preventing the luteinizing hormone surge that triggers ovulation. The progestogen also thickens cervical mucus and creates an endometrial environment that is unsuitable for implantation.

The dosing regimen for Monostep is determined by the prescribing clinician. Typically, it involves a 21‑day series of active tablets followed by a placebo interval, but the exact schedule and any adjustments must be set by a qualified healthcare professional.

Monostep is not intended for use during pregnancy; if pregnancy occurs, the product should be discontinued. Limited safety data exist for breastfeeding, and use is generally not recommended without medical guidance. Physicians should assess the risk‑benefit profile for each individual.

To order Monostep, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Monostep offers efficacy comparable to other combined oral contraceptives that contain an estrogen‑progestogen pair. Differences lie mainly in the specific estrogen dose and the type of progestogen; levonorgestrel provides a well‑studied progestogenic profile, while the ethinylestradiol dose influences cycle control and side‑effect potential.

Monostep tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and store out of reach of children. Do not use if the packaging is damaged or tablets appear discolored.

Monostep is taken orally, once daily, at the same time each day. It may be taken with or without food. Consistent daily intake is important to maintain contraceptive effectiveness; missed tablets should be managed according to the prescribing information.

The most serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial thrombosis (stroke or heart attack), severe hypertension, development of hepatic adenomas, and severe allergic reactions such as anaphylaxis. Prompt medical attention is required if any of these events occur.

Monostep should be avoided in women with a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, known hypersensitivity to ethinylestradiol, levonorgestrel or any tablet excipients, and in smokers over 35 years of age. Consultation with a healthcare provider is essential before initiating therapy.